Erika P. Hamilton, MD

Erika P. Hamilton, MD, director of the breast cancer and gynecologic cancer research program at the Sarah Cannon Research Institute, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer.

OP-1250 is a novel therapy that is different to other agents, says Hamilton. It is a complete estrogen receptor (ER) antagonist with unique properties that shows promise for this particular patient population. OP-1250 has also demonstrated activity preclinically in both wild-type and ESR1 models, and it turns off both the AF1 and AF2 domain, says Hamilton.

Articles

Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.

Exploring the Rationale for OP-1250 in Advanced HR-Positive HER2-Negative Breast Cancer

Erika P. Hamilton, MD, director of the breast and gynecologic research program at Sarah Cannon Research Institute, discusses the results from a phase II study of abemaciclib (Verzenio) plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.

The progression-free survival (PFS) range was 6.5 months to 9.1 months in this study and was not statistically significant across arms. Hamilton says the single-agent abemaciclib had equal activity in regard to PFS. Hamilton also noted the arm receiving 200 mg of abemaciclib had a response rate of 29% compared to 19% in the previous MONARCH trial.

Videos

Erika P. Hamilton, MD, discusses the results from a phase II study of abemaciclib plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.

Findings With Abemaciclib Plus Tamoxifen in Advanced Breast Cancer

Hamilton says there are currently not very many "good" drugs for treating these metastases. She adds that the mainstay for treating these metastases is usually some form of radiation therapy, such as whole brain radiation.

Dr. Erika P. Hamilton on Difficulties of Treating Brain Metastases in Breast Cancer

Erika P. Hamilton , MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer. She cites the approval of drugs like pertuzumab and T-DM1 over the years as a step in the right direction for treatment of HER2-positive breast cancer, and goes on to say that oncologists have more of an option in treatment now than ever before.

Hamilton says the biggest challenge oncologists face now is figuring out where to place these drugs in the treatment paradigm. She says as T-DM1 and pertuzumab are used more in the neoadjuvant or adjuvant space, the metastatic sequence may be up in the air more.

Erika P. Hamilton, MD, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer.

Erika P. Hamilton, MD | Authors

Articles

Exploring the Rationale for OP-1250 in Advanced HR-Positive HER2-Negative Breast Cancer

Findings With Abemaciclib Plus Tamoxifen in Advanced Breast Cancer

Dr. Erika P. Hamilton on Difficulties of Treating Brain Metastases in Breast Cancer

Dr. Erika P. Hamilton on the Shifting Treatment Paradigm in HER2-Positive Breast Cancer